OXALIPLATIN SOLUTION

Krajina: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktívna zložka:

OXALIPLATIN

Dostupné z:

PFIZER CANADA ULC

ATC kód:

L01XA03

INN (Medzinárodný Name):

OXALIPLATIN

Dávkovanie:

5MG

Forma lieku:

SOLUTION

Zloženie:

OXALIPLATIN 5MG

Spôsob podávania:

INTRAVENOUS

Počet v balení:

10/20/40ML

Typ predpisu:

Prescription

Terapeutické oblasti:

ANTINEOPLASTIC AGENTS

Prehľad produktov:

Active ingredient group (AIG) number: 0152220003; AHFS:

Stav Autorizácia:

APPROVED

Dátum Autorizácia:

2017-06-01

Súhrn charakteristických

_ _
_Pr_
_Oxaliplatin – Product Monograph_
_ _
_Page 1 of 64_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
OXALIPLATIN
Oxaliplatin Injection, 5 mg/mL
Sterile concentrate 50 mg / 10 mL, 100 mg / 20 mL, 200 mg / 40 mL for
intravenous infusion
Antineoplastic Agent
Pfizer Canada ULC
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5
Date of Initial Authorization:
DEC 16, 2015
Date of Revision:
MAY 10, 2023
Submission Control Number: 270750
_ _
_Pr_
_Oxaliplatin – Product Monograph_
_ _
_Page 2 of 64_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Reproductive Health: Female
and Male Potential
05/2023
7 WARNINGS AND PRECAUTIONS, 7.1.2 Breast-feeding
05/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1.
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 4
4
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.1
Dosing Considerations
............................................................................................
5
4.2
Recommended Dose and Dosage Ad